Combined treatment with PTH (1–34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats
- 24 May 2005
- Vol. 37 (1) , 87-95
- https://doi.org/10.1016/j.bone.2005.03.013
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized miceBone, 2004
- PTH Differentially Regulates Expression of RANKL and OPGJournal of Bone and Mineral Research, 2004
- Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in RatsJournal of Bone and Mineral Research, 2003
- OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized RatsEndocrinology, 2001
- Programmed Administration of Parathyroid Hormone Increases Bone Formation and Reduces Bone Loss in Hindlimb-Unloaded Ovariectomized RatsEndocrinology, 1998
- The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1-34) on Bone Histomorphometry and Serum Chemistry in RatsEndocrinology, 1997
- Effects of sodium fluoride and alendronate on the bone mineral in minipigs: A small-angle X-ray scattering and backscattered electron imaging studyJournal of Bone and Mineral Research, 1996
- The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?Bone, 1995
- Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfacesBone, 1993
- Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.BMJ, 1980